Ask AI
ProCE Banner Events

Share

Evening With the Experts: Discussing the Rapidly Evolving Treatment Landscape for EBC

Join us in person at ASCO 2023 or virtually for this 1.5-hour live, CME-certified satellite symposium on personalizing therapy for early breast cancer. This interactive event features expert perspectives on the evolving role of biomarkers for perioperative treatment with targeted therapy and immunotherapy. Bring your questions for the question and answer session with the expert faculty.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Credits Available

1.5

Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who care for patients with early-stage breast cancer.

Time and location

Friday, June 02, 2023

7:00 PM - 8:30 PM Central Time (CT)

In-personVirtual

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Salon A 3-4

Agenda

Registration & Dinner: 6:30 - 7:00 PM CT

Symposium: 7:00 - 8:30 PM CT

Welcome, Overview, Audience Polling Questions
Joyce O’Shaughnessy, MD

Case Discussion 1: Evaluating and Managing High-Risk Disease in HR+/HER2- EBC (Without gBRCA)
Komal Jhaveri, MD

Case Discussion 2: Germline BRCA Testing and Targeting gBRCA1/2 Pathogenic or Likely Pathogenic Variants in HER2- EBC
Mark Robson, MD

Case Discussion 3: The New Treatment Paradigm and Ongoing Questions for Early-Stage TNBC
Joyce O’Shaughnessy, MD

Panel Discussion, Audience Question and Answer Session
Joyce O’Shaughnessy, MD; Komal Jhaveri, MD; Mark Robson, MD

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Room Name

Salon A 3-4

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, confidence, and competence to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer. 

Target Audience
This program is intended for medical oncologists and other healthcare professionals who care for patients with early-stage breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

Program Learning Goal

This activity aims to improve learners' knowledge, confidence, and competence to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer. 

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.